Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRMD NASDAQ:DSGN NASDAQ:MDWD NASDAQ:OCS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRMDCorMedix$8.67$7.94$6.13▼$17.43$680.18M1.461.12 million shs2.51 million shsDSGNDesign Therapeutics$12.44+4.3%$12.28$3.33▼$17.25$745.11M1.63808,393 shs1.04 million shsMDWDMediWound$14.24+0.3%$15.96$13.54▼$21.25$182.50M0.16112,261 shs69,383 shsOCSOculis$11.22-0.7%$23.78$10.52▼$34.47$655.22M0.231.26 million shs771,997 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRMDCorMedix+0.12%-1.14%+9.61%+37.62%-37.80%DSGNDesign Therapeutics+11.29%+11.91%+11.50%+16.28%+224.18%MDWDMediWound+2.38%+2.45%-13.41%-16.32%-28.21%OCSOculis-1.31%+3.01%-59.74%-55.46%-42.73%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRMDCorMedix$8.67$7.94$6.13▼$17.43$680.18M1.461.12 million shs2.51 million shsDSGNDesign Therapeutics$12.44+4.3%$12.28$3.33▼$17.25$745.11M1.63808,393 shs1.04 million shsMDWDMediWound$14.24+0.3%$15.96$13.54▼$21.25$182.50M0.16112,261 shs69,383 shsOCSOculis$11.22-0.7%$23.78$10.52▼$34.47$655.22M0.231.26 million shs771,997 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRMDCorMedix+0.12%-1.14%+9.61%+37.62%-37.80%DSGNDesign Therapeutics+11.29%+11.91%+11.50%+16.28%+224.18%MDWDMediWound+2.38%+2.45%-13.41%-16.32%-28.21%OCSOculis-1.31%+3.01%-59.74%-55.46%-42.73%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRMDCorMedix 2.75Moderate Buy$15.0073.01% UpsideDSGNDesign Therapeutics 2.88Moderate Buy$16.5032.64% UpsideMDWDMediWound 2.25Hold$34.00138.76% UpsideOCSOculis 2.80Moderate Buy$38.33241.65% UpsideCurrent Analyst Ratings BreakdownLatest MDWD, DSGN, CRMD, and OCS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026OCSOculis HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/3/2026OCSOculis JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$42.00 ➝ $23.006/1/2026OCSOculis Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$49.00 ➝ $38.006/1/2026OCSOculis Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$50.00 ➝ $40.006/1/2026OCSOculis GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$75.00 ➝ $45.006/1/2026OCSOculis HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$47.00 ➝ $26.006/1/2026OCSOculis Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$46.00 ➝ $38.005/28/2026MDWDMediWound HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$36.005/27/2026MDWDMediWound OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$33.00 ➝ $32.005/20/2026OCSOculis GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$75.005/20/2026OCSOculis GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 6/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRMDCorMedix$400.05M1.70$2.05 per share4.23$5.14 per share1.69DSGNDesign TherapeuticsN/AN/AN/AN/A$3.73 per shareN/AMDWDMediWound$14.48M12.64N/AN/A$3.40 per share4.19OCSOculisN/AN/AN/AN/A$4.08 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRMDCorMedix$163.05M$2.134.0748.17N/A45.25%45.57%24.76%8/6/2026 (Estimated)DSGNDesign Therapeutics-$69.79M-$1.20N/AN/AN/AN/A-33.07%-31.29%8/6/2026 (Estimated)MDWDMediWound-$23.88M-$2.26N/AN/AN/A-180.30%-67.22%-31.87%8/13/2026 (Estimated)OCSOculis-$119.44M-$2.13N/AN/AN/A-8,460.67%-56.78%-45.62%8/6/2026 (Estimated)Latest MDWD, DSGN, CRMD, and OCS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/27/2026Q1 2026MDWDMediWound-$0.65-$0.23+$0.42-$0.23$3.37 million$1.48 million5/14/2026Q1 2026CRMDCorMedix$0.35$0.43+$0.08$0.43$104.96 million$127.43 million5/8/2026Q1 2026OCSOculis-$0.49-$0.63-$0.14-$0.61$0.25 million$0.26 million4/28/2026Q1 2026DSGNDesign Therapeutics-$0.36-$0.29+$0.07-$0.29N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRMDCorMedixN/AN/AN/AN/AN/ADSGNDesign TherapeuticsN/AN/AN/AN/AN/AMDWDMediWoundN/AN/AN/AN/AN/AOCSOculisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRMDCorMedix0.332.972.74DSGNDesign TherapeuticsN/A22.2822.28MDWDMediWoundN/A2.412.19OCSOculis0.015.185.18Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRMDCorMedix34.18%DSGNDesign Therapeutics56.64%MDWDMediWound46.83%OCSOculis22.30%Insider OwnershipCompanyInsider OwnershipCRMDCorMedix3.50%DSGNDesign Therapeutics17.10%MDWDMediWound9.20%OCSOculisN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRMDCorMedix3078.45 million75.71 millionOptionableDSGNDesign Therapeutics4062.46 million51.78 millionOptionableMDWDMediWound8012.85 million11.67 millionOptionableOCSOculis257.98 millionN/ANot OptionableMDWD, DSGN, CRMD, and OCS HeadlinesRecent News About These CompaniesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCSJune 18 at 10:00 AM | prnewswire.comOCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law FirmJune 17 at 9:44 AM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCSJune 16 at 5:03 PM | globenewswire.comOCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law FirmJune 11, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCSJune 11, 2026 | prnewswire.comOculis Holding AG to Present Privosegtor Development at Clinical Trials at the Summit 2026June 11, 2026 | quiverquant.comQOculis Holding AG to Present on Privosegtor at Clinical Trials at the Summit 2026June 11, 2026 | quiverquant.comQOculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026June 11, 2026 | globenewswire.comOculis Publishes Notifications of Transactions by Persons Discharging Managerial ResponsibilitiesJune 10, 2026 | globenewswire.comOculis Publishes Notifications of Transactions by Persons Discharging Managerial ResponsibilitiesJune 9, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCSJune 9, 2026 | globenewswire.comOculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye DiseaseJune 9, 2026 | globenewswire.comNan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug StumblesJune 8, 2026 | aol.comAOculis Holding AG to Provide Update on Late-Stage Portfolio at 47th Annual Goldman Sachs Global Healthcare ConferenceJune 8, 2026 | quiverquant.comQOculis to Present at the 47th Annual Goldman Sachs Global Healthcare ConferenceJune 8, 2026 | globenewswire.comOCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law FirmJune 8, 2026 | prnewswire.comOculis Holding AG (OCS) Securities Fraud Investigation - Levi & KorsinskyJune 8, 2026 | prnewswire.comLost Money on Oculis Holding AG (OCS)? Contact Levi & Korsinsky About InvestigationJune 7, 2026 | newsfilecorp.comNOCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law FirmJune 4, 2026 | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCSJune 4, 2026 | prnewswire.comOculis Shelves FDA Filing After Phase 3 DME Trials Miss Key Vision GoalsMay 31, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMDWD, DSGN, CRMD, and OCS Company DescriptionsCorMedix NASDAQ:CRMD$8.67 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$8.65 -0.02 (-0.17%) As of 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.Design Therapeutics NASDAQ:DSGN$12.44 +0.51 (+4.27%) Closing price 04:00 PM EasternExtended Trading$12.44 0.00 (0.00%) As of 04:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.MediWound NASDAQ:MDWD$14.24 +0.04 (+0.28%) Closing price 04:00 PM EasternExtended Trading$14.25 +0.01 (+0.07%) As of 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.Oculis NASDAQ:OCS$11.22 -0.08 (-0.71%) Closing price 04:00 PM EasternExtended Trading$11.14 -0.08 (-0.67%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge Jabil Just Gave Investors a Stronger Reason to Buy the Dip USA Rare Earth Just Moved Closer to Commercial Reality After an Initial Panic, Wall Street's Leaning Into Apple's New Siri AI CoreWeave Insider Sales Look Big, But Should Investors Worry? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
